Tu1389 THE FEASIBILITY AND VALUE OF CYST WALL BIOPSY USING MICRO FORCEPS IN THE DIAGNOSIS OF PANCREATIC CYSTS

Wilen, Jonathan; Visrodia, Kavel; Lan, Gloria; Sethi, Amrita; Poneros, John M.; Gonda, Tamas A.

doi:10.1016/j.gie.2019.03.1046

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This meta-analysis included a total of 11 studies (n = 518) 26 27 28 29 30 31 32 33 34 35 36 . A PRISMA flow chart of search results is shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

Endoscopic ultrasound-guided through-the-needle microforceps biopsy improves diagnostic yield for pancreatic cystic lesions: a systematic review and meta-analysis

McCarty

Rustagi

2020

Endosc Int Open

View full text Add to dashboard Cite

Background and study aims Given variable diagnostic yield of endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNA) for pancreatic cystic lesions (PCLs), a through-the-needle (TTN) microforceps biopsy device passed through a 19-gauge FNA needle has been devised to improve tissue sampling. This was a systematic review and meta-analysis to evaluate the feasibility, diagnostic yield, and safety of EUS-guided TTN microforceps biopsy for diagnosis of PCLs. Methods Individualized searches were developed in accordance with PRISMA and MOOSE guidelines. This was a cumulative meta-analysis performed by calculating pooled proportions with rates estimated using random effects models. Measured outcomes included pooled technical success, diagnostic yield, accuracy, and procedure-associated adverse events (AEs) as well as comparison to conventional FNA. Results Eleven studies (n = 518 patients; mean age 64.13 ± 5.83 years; 58.19 % female) were included. Mean PCL size was 33.39 ± 3.72 mm with the pancreatic head/uncinate (35.50 %) being the most common location. A mean of 2.47 ± 0.92 forceps passes were performed with a mean of 2.79 ± 0.81 microbiopsies obtained per lesion. Pooled technical success was 97.12 % (95 % CI, 93.73–98.71; I2 = 34.49) with a diagnostic yield of 79.60 % (95 % CI, 72.62–85.16; I2 = 56.00), and accuracy of 82.76 % [(95 % CI, 77.80–86.80; I2 = 0.00). The pooled serious adverse event rate was 1.08 % (95 % CI, 0.43–2.69; I2 = 0.00). Compared to conventional FNA, TTN microforceps biopsy resulted in significant improvement in diagnostic yield [OR 4.79 (95 % CI: 1.52–15.06; P = 0.007)] and diagnostic accuracy [OR 8.69 (95 % CI, 1.12–67.12; P = 0.038)], respectively. Conclusions EUS-guided TTN microforceps biopsy appears to be safe and effective for diagnosis of PCLs with improvement in diagnostic yield and accuracy when compared to FNA alone.

show abstract

“…This meta-analysis included a total of 11 studies (n = 518) 26 27 28 29 30 31 32 33 34 35 36 . A PRISMA flow chart of search results is shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

Endoscopic ultrasound-guided through-the-needle microforceps biopsy improves diagnostic yield for pancreatic cystic lesions: a systematic review and meta-analysis

McCarty

Rustagi

2020

Endosc Int Open

View full text Add to dashboard Cite

show abstract

“…The study by Cheesman et al is an abstract, which also scored 5 on our scale and was rated as low quality in the published meta-analysis. In the 7 studies, 35,36,[39][40][41][42][43] including Crino et al and Cheesman et al, the pooled OR was 4.82 (95% confidence interval, 1.65-14.31; P Z .004, I 2 Z 83%). When Crino et al and Cheesman et al were removed based on down-rating as outliers, the OR became insignificant (OR, 2.33; 95% confidence interval, .9-6.03; P Z .08, I 2 Z 76%) ( Supplementary Fig.…”

Section: Effect Of Down-ratingmentioning

confidence: 92%

Quality assessment for systematic reviews and meta-analyses of cohort studies

Qumseya

2021

Gastrointestinal Endoscopy

View full text Add to dashboard Cite

Background and Aims: There is a growing need for valid, efficient, and easy scoring scales to rate the quality of cohort studies. We aimed to develop and validate a quality assessment score to be used for cohort studies. Methods: We followed a rigorous process to establish content, face, and construct validity. Most questions were scored at 0 or 1. Inter-rater reliability and test-retest reliability were assessed using the Spearman correlation coefficient (r s) and Cohen's k statistic. Internal consistency was measured using the Kuder-Richardson formula 20 (KR20). Results: The final tool consists of 9 questions with a maximum score of 10. The inter-rater reliability was high with the Spearman correlation coefficient (r s Z .66). Agreement for inclusion was 90%. Test-retest reliability was high. For rater 1, r s Z .91, k Z .38 for scores, and k Z 1 for inclusion. For rater 2, r Z .94, 80% agreement for scores, and 100% agreement for inclusion. Internal consistency was reasonable based on 2 studies: KR20 Z .21 and KR20 Z .65. The novel scale rated highest in efficiency, understandably, ease of use, and ease of interpretation when compared with 3 other scales. Conclusions: This novel scale has favorable performance characteristics, is efficient to conduct, and is easy to interpret and will be very helpful for physicians and researchers conducting systematic reviews and meta-analyses. (Gastrointest Endosc 2021;93:486-94.) In recent years, clinicians have come to recognize that medical practices need to be based on systematic review of all available evidence. 1 In 2011, the Institute of Medicine, now the National Academy of Medicine, defined guidelines as "recommendations intended to optimize patient care that are informed by a systematic review of evidence." (p. 25)2 This evidence-based approach has become a critical aspect of the practice of medicine. The process is transparent, based on rigorous methodology, and reproducible. Adopting evidence-based guidelines has changed the way physicians, medical societies, and guideline panels use the medical literature to make clinical decisions. 3 Performing systematic reviews and meta-analyses are key components of all medical guidelines at this point. 4 An integral part of conducting a systematic review is to rate the quality of individual articles. 5 For this purpose, many scoring systems have been developed and validated. 6,7 However, the use of such quality scores has been fraught with several shortcomings. First, a large gap remains in the area of scoring cohort studies. These include prospective or retrospective studies, which were not designed as randomized trials. Although many scoring systems exist for randomized trails, 8 only a few scores have been developed for cohort studies. 9-11 Second, previous scales can be complex to use, score, and interpret. Last, many scoring tools did little to address specific concerns relating to the process of meta-analysis. We believe the ideal quality assessment scale for cohort studies Abbreviations: BE, Barrett's esophagus; KR20,...

show abstract

Evidence-Based Assessment of Diagnostic Performance of Currently Available Needles and Techniques for EUS-Guided Tissue Acquisition

Facciorusso

Muscatiello

2021

Endoscopic Ultrasound Management of Pancreatic Lesions

View full text Add to dashboard Cite

Tu1389 THE FEASIBILITY AND VALUE OF CYST WALL BIOPSY USING MICRO FORCEPS IN THE DIAGNOSIS OF PANCREATIC CYSTS

Cited by 6 publications

References 0 publications

Endoscopic ultrasound-guided through-the-needle microforceps biopsy improves diagnostic yield for pancreatic cystic lesions: a systematic review and meta-analysis

Endoscopic ultrasound-guided through-the-needle microforceps biopsy improves diagnostic yield for pancreatic cystic lesions: a systematic review and meta-analysis

Quality assessment for systematic reviews and meta-analyses of cohort studies

Evidence-Based Assessment of Diagnostic Performance of Currently Available Needles and Techniques for EUS-Guided Tissue Acquisition

Contact Info

Product

Resources

About